Oxygen is a crucial nutrient for biological organisms. At the cell level, the survival of many types of cells relies on a continuous supply of oxygen in their growth environment. At the organ level of an animal, the lack of oxygen in the blood, even for brief periods, may cause organ dysfunction that could lead to catastrophic events such as brain damage, lung failure, or even death. There is a need for creating an oxygenated environment for culturing animal cells and a need for providing oxygenated blood for treating related diseases.
This application relates to systems and methods for culturing cells and for oxygenating blood.
One general aspect of the invention features a cell culture apparatus that includes a rotatable vessel having a wall for defining a culture chamber, and an inlet formed in the wall enabling fluid communication between the culture chamber and an external fluid source. In some examples, the wall has an inner surface configured to promote gas-inner surface contact. An actuator is coupled to the vessel for rotating the vessel about a first axis to increase the level of dissolved oxygen in a fluid in the culture chamber.
Embodiments of this aspect may include one or more of the following features.
The vessel has an outlet enabling fluid communication between the culture chamber and a sensor. The sensor can be used for measuring a fluid condition in the culture chamber, for example, the level of dissolved oxygen or the pH level of the fluid in the culture chamber.
A controller is provided for receiving a signal from the sensor and for determining the speed of rotation according to the received signal.
The external fluid source includes a liquid source and a gas source. A valve is provided in the system for selectively coupling the liquid source and the gas source to the inlet of the rotatable vessel. The liquid source can include a culture medium. The gas source can include one or more of the following: air, oxygen, carbon dioxide, and nitrogen.
A housing is provided for coupling the vessel to the actuator. A movable platform can be coupled to the housing for translating the vessel along a second axis.
The inner surface of the wall is characterized by micro-structures or nano-structures.
The vessel can be disposed in an at least partially closed environment (e.g., an incubator) of controlled temperature or controlled gaseous composition.
Another general aspect of the invention features a method for oxygenating a culture medium, for example, performed using the cell culture apparatus described above. The method includes introducing a culture medium into a culture chamber at least partially filled with gas, wherein the culture chamber is defined by a wall of a vessel, and an inner surface of the wall is configured to promote gas-inner surface contact. The method also includes rotating the vessel to create a relative movement of the culture medium with respect to the inner surface of the wall of the vessel to increase the level of dissolved oxygen in the culture medium.
Embodiments of this method may include one or more of the following features.
In rotating the vessel, microscopic bubbles carrying oxygen molecules are generated.
The method can also include measuring a fluid condition of the culture medium and controlling a speed of rotation according to the measured fluid condition.
The fluid condition includes one or more of the following: a pH level, a dissolved oxygen level, a carbon dioxide level, and a temperature.
A third general aspect of the invention features a culture system that has an oxygenation apparatus configured for oxygenating a culture medium. The oxygenation apparatus includes a vessel having an inlet for receiving the culture medium to be oxygenated, an outlet for providing oxygenated culture medium, and a wall with an inner surface configured to promote gas-inner surface contact; and an actuator coupled to the vessel for rotating the vessel to increase the level of dissolved oxygen in the culture medium. A culture apparatus is configured for receiving the oxygenated culture medium from the oxygenation apparatus. The culture apparatus includes a port for receiving a biological material into an interior of the culture apparatus; and an inlet in fluid communication with the interior of the culture apparatus to deliver the oxygenated culture medium into contact with the biological material.
Embodiment of this aspect may include one or more of the following features.
The biological material received in the culture apparatus includes cells or tissues.
The culture apparatus includes a perfusion column, which may be configured to receive a bio-compatible matrix suitable for cell culture. The bio-compatible matrix includes, for example, a microcarrier and a paper carrier. Some of these matrixes include polymer fibers, which can be woven or non-woven.
The flow rate of the culture medium exiting the perfusion column is controlled based on a height of the perfusion column. The flow rate of the culture medium entering the perfusion column is controlled to be substantially equal to the flow rate of the culture medium exiting the perfusion column. In one embodiment, the perfusion column is mounted on an adjustable stand configured for adjusting the height of the perfusion column.
The system also includes a pump for generating a flow of the oxygenated culture medium to be received by the culture apparatus.
A controller can be used for controlling a speed of the flow of the oxygenated culture medium, and can be further used to control a rotational or an orbital movement speed of the vessel of the oxygenation apparatus.
In some examples, the vessel of the oxygenation apparatus has an inverted frusto-conical bottom or cone-shaped round bottom.
A fourth general aspect of the invention features a culture system that includes a housing having a first terminus and a second and close terminus opposed to the first terminus, the first terminus having a port for receiving and dispensing a culture medium. A tubular member is disposed within an interior of the housing. The tubular member has a first open end; a second and close end positioned at the second terminus of the housing; and a disk membrane coupled to the first open end for at least partially enclosing an interior of the second tubular member to define a culture chamber, wherein the disk member includes at least an opening enabling fluid communication between the culture chamber and an exterior of the second tubular member. An actuator is coupled to the housing for rotating the housing to increase the level of dissolved oxygen in a fluid in the culture chamber.
Embodiments of this aspect may include one or more of the following features.
The tubular member is detachably disposed within the interior of the housing, and configured to receive a bio-compatible matrix suitable for cell culture through its first open end. An inner surface of the tubular member may be configured to promote gas-inner surface contact.
A fifth general aspect of the invention features a cell culture apparatus that includes a tubular member having a first end and a second and close end opposed to the first end, the first end having a port for receiving and dispensing a culture medium; a bio-compatible matrix disposed within an interior of the tubular member; and a disk member detachably disposed within the interior of the tubular member for substantially confining the bio-compatible matrix within a culture chamber defined between the disk member and the second end of the tubular member. The disk member includes at least an opening for permitting a flow of the culture medium into the culture chamber.
In one embodiment, a cap may be coupled to the first end of the tubular member for sealingly enclosing the interior of the tubular member.
A sixth general aspect of the invention features a cell culture system that includes an elongated member having a first close end; a second close end opposed to the first close end; a wall defining a culture chamber at least partially filled with gas; and an inlet formed in the wall capable of receiving a culture medium. A shaft is positioned substantially within the culture chamber, with its first end and second end respectively positioned at a corresponding end of the elongated member. A set of one or more disk elements is concentrically mounted on the shaft. An actuator is mechanically coupled to the shaft for rotating the disk elements about a longitudinal axis of the shaft for inducing a relative movement of the culture medium with respect to an inner surface of the wall of the elongated member. A sensor detects the level of dissolved oxygen in the culture medium contained in the culture chamber.
Embodiments of this aspect may include one or more of the following features.
A bio-compatible matrix can be disposed at a lower section of the interior of the elongate member. The bio-compatible matrix may include polymer fibers.
A controller is provided for receiving a signal from the sensor indicative of the level of dissolved oxygen in the culture medium, and further configured for controlling a speed of rotation of the shaft based on the received signal from the sensor.
The elongated member further includes a second inlet for introducing a flow of gas into the interior of the elongated member.
The controller is also configured for controlling a gaseous composition in the interior of the elongated member.
A seventh general aspect of the invention features a system for oxygenating blood and delivering the oxygenated blood to a subject. The system includes (1) a blood pump assembly adapted for coupling to a supply of blood; (2) a blood oxygenation assembly coupled to the blood pump assembly; (3) a delivery assembly; and (4) a control assembly.
The blood oxygenation assembly can receive blood from the blood pump assembly and oxygenate the blood. In one example, the blood oxygenation assembly has a blood bioreactor/oxygenator that includes (a) a housing including a wall; (b) a first inlet in the housing adapted to deliver oxygen-containing gas stream into contact with a first surface of the wall; (c) a second inlet in the housing adapted to deliver the blood into contact with a second surface of the wall, wherein the blood bioreactor/oxygenator allows a movement of the blood so that the blood contacts with the first surface to form oxygenated blood; and (d) a first outlet and a second outlet in the housing for expelling CO2-containing gas and the oxygenated blood, respectively. The delivery assembly is coupled to the second outlet and is adapted to deliver the oxygenated blood to the subject; and the control assembly is coupled to the blood oxygenation assembly.
In one embodiment, the blood bioreactor/oxygenator allows the movement of the blood therein so that the blood and the oxygen-containing gas repeatedly and consecutively contact the first surface. For example, the movement can be a circular movement. In another embodiment, the housing defines a chamber that includes an inverted frusto-conical bottom or cone-shaped round bottom configured lower section.
In the above-described system, the blood bioreactor/oxygenator can further include a pH probe, a temperature probe, or a dissolved oxygen (DO) probe. In one embodiment, the system can also include a treatment assembly that removes an unwanted agent from the blood. Examples of such unwanted agent include a chemical agent, a bio molecule, an antibody, a virus, or a cell. In another embodiment, the system also includes a light/radiation source for killing an unwanted cell in the blood.
Further aspects of the invention provide a method for oxygenating blood of a subject (human or none-human animal) using the above-described system and a method can be used to remove an unwanted agent from the blood of a subject.
The invention also features a method of using the above-describe system for treating a subject having a disorder characterized with defect in blood oxygenation. Examples of the disorders include cardiovascular disorders (e.g., myocardial infarction), lung failure, or other respiratory disorders such as acute respiratory distress syndrome (ARDS). The invention also features methods for treating a subject having cancer and tumor metastasis, such as leukaemia, lymphoma, and sarcoma. The invention also features methods for treating a subject having an infection with a microbe, such as a bacterial cell, a yeast cell, or a virus. Each of the method include a step of removing the unwanted agent (e.g., cancer cell, bacterial cell, a yeast cell, or a virus) from the blood using the above-describe system.
Other features and advantages of the invention are apparent from the following description, and from the claims.
Oxygen is an essential nutrient for cells. Oxygen deprivation for even brief periods of time may result in cell damage, which may lead to organ dysfunction or failure. For example, heart attack and stroke victims experience blood flow obstructions or diversions that prevent oxygen from being delivered to the cells of vital tissues. Also, without oxygen, the heart and brain progressively deteriorate. Severe cases of oxygen deprivation can result in complete organ failure and even death. Less severe cases typically involve costly hospitalization, specialized treatments, and lengthy rehabilitation. In many biological and clinical settings, the level of oxygen in a culture medium or blood is closely monitored by measuring the concentration of dissolved oxygen (DO), i.e., the relative amount of oxygen dissolved or carried in a medium.
This application discloses various systems and techniques for oxygenating a cell culture environment and/or blood, for example, by increasing the DO level in a liquid solution, without necessarily using the conventional air bubbling or sparging techniques. These systems and techniques have a wide range of biological and medical applications.
This section describes various embodiments of a cell culture system capable of providing an oxygenated culture medium for use in many types of cell culture schemes.
2.1 System with Rotating Bioreactor
In this embodiment, the bioreactor 110 includes a wall 112 for defining a culture chamber 114 in which cells or tissues can grow. An inlet 116 is formed in the wall 112 to allow the passage of a culture medium 122 or a gas 124 into the culture chamber 114 via the use of a three-way valve 126. Depending on the particular application, the gas 124 may contain air, oxygen, nitrogen, carbon dioxide, or a combination thereof. An outlet 116 is also formed in the wall 112 to allow the culture medium inside the chamber 114 to be disposed to a waste collection 132, or alternatively, be tested by a sensor 134 (e.g., a pH probe, a DO probe, and a temperature probe).
The bioreactor 110 can be mounted onto a housing 140 mechanically coupled to a platform 150. An actuator 160 (e.g., a rotary motor) is coupled to the housing 140 for causing the bioreactor 110 to rotate or roll about an axis 142 at a speed ω, which may be controlled by a speed controller 170. The platform 150 may be stationary, or instead be movable along the x and y axes (shown in the figure), which can in turn cause cyclic movement of the bioreactor 110 along those two directions.
Referring to
In some examples, the bioreactor 110 is made of a glass or plastic container having a smooth inner surface. The bioreactor can be made in either disposable or reusable forms. In some examples, the bioreactor 110 includes a disposable container 111 (e.g., a plastic bag) positioned inside an autoclavable container (e.g., a glass housing).
In some examples, to further increase the oxygenation performance or to support high-density cell culture, the bioreactor 110 is made of materials with micro- or nano-level surface features. For example, the bioreactor of
In some examples, the wall of the bioreactor 110 is configured to feature “hilly” surface with microscopic surface details discernable at nanometer resolution (e.g., through electron microscopy). Such configurations may provide improved oxygen transfer characteristics in certain applications. For example, microscopic hills (or concavities) formed at 1˜2000 nanometers (e.g., 5, 10, 50, 100, 200, 500, 1000, or 1500 nanometers) in diameter can break the surface tension of the culture medium in contact with the wall, thereby generating microscopic bubbles. The wall of the bioreactor can be made from various materials, including for example glass, silica glass, steel, aluminum, array, and different types of plastics. It should be noted that even though the bubbles generated during the rotation of the bioreactor may not always be uniform in size or in spatial distribution, the presence of a significant portion of microscopic bubbles containing oxygen molecules can still result in an increase in the DO level of the culture medium.
Note that the rotational or rolling speed of the bioreactor 110 can be controlled by actively monitoring the DO level of the culture medium in the bioreactor. For example, a DO sensor 134 may be employed to detect the DO level in real time and report the measurement to a computer 180. The computer 180 compares the actual DO level with a target level to determine whether to increase or decrease the rotational speed of the motor 160. In some examples, the rotation of the bioreactor is controlled such that the culture medium inside the bioreactor appears to stay relative static, thereby reducing or limiting the impact of hydro-mechanical stress (e.g., flow-induced shear stress) on cells attached to a matrix. This can be a desirable feature in some applications, as impeller-based bioreactors tend to generate shear forces or agitation forces that may damage cells in a suspension culture. In some further examples, the rotational or rolling speed of the bioreactor is also determined based on the desired amount of sweeping force (or the desired speed of in-chamber medium current), which may correspond to the particular surface characteristics of the bioreactor.
In some examples, the tubular member 630 can be detached from the housing 620 to allow cells or tissues to be placed inside the tubular member 630. In some other examples, the tubular member 630 is fixed inside the housing 620, in which case cells or tissues can be injected into the tubular member 630 through an internal passage 650. The culture medium can be introduced through the internal passage 650 into the culture chamber. In some examples, during the rotation or rolling of the bioreactor 610, the culture medium inside the culture chamber stays relatively level.
Note that some or all of the embodiments described above can be placed in a controlled environment similar to the one shown in
2.2 System with “Artificial Lung”
The oxygenation assembly 820 includes a reactor 822 having an inlet 824 for receiving a culture medium provided by a medium reservoir 810 into an interior of the reactor to be oxygenated. The reactor 822 is mounted onto a rotor 828, which causes high speed orbital movement of the reactor, which in turn generates high levels of DO in the culture medium. Exemplary configurations of the reactor 822 and its operation are discussed in detail in International Patent Application Publication No. WO2007/142664A1, titled “A Method to Increase Dissolved Oxygen in a Culture Vessel,” filed September 2006, and International Patent Application Publication No. WO2006/138143A1, titled “Suspension Culture Vessels,” filed Jun. 8, 2006, the content of which is incorporated herein by reference. For example, the reactor 822 can be made of a plastic container having an inverted frusto-conical bottom or a cone-shaped round bottom. In some other examples, the reactor 822 can be implemented as a classical impellor-based deep-tank reactor.
Once being oxygenated, the culture medium inside the reactor 822 is circulated by a pump 830 (e.g., a peristaltic pump) through an outlet 826 to be provided to the cell culture apparatus 840. In one example, the cell culture apparatus 840 includes a perfusion column 842, within which a bio-compatible matrix (e.g., a paper carrier or a microcarrier) can be disposed for promoting cell growth. The original cell sources can be obtained, for example, from a bioreactor (such as the one shown in
The oxygenated culture medium generated by the reactor 822 flows into an inlet 844 of the perfusion column 842, passes through the matrix to which cells are attached, and exits at an outlet 846 of the perfusion column 842 to a medium reservoir 810 or to the reactor 822 via inlet 824. As such, the medium is re-circulated through the system. In another embodiment, the medium can exist at the outlet 846 and collected to a harvest (or waste collection) 850. In some examples, the perfusion speed within the column 842 is controlled by a hydrostatic pressure caused by gravity, for example, as a function of the relative height of the column (as shown by ΔH in
The above-described perfusion method is scalable. For example, the culture medium can be controlled to evenly perfuse into the paper carrier inside the column regardless of the size of the column. In certain applications, this feature can be desirable, especially when compared with some convention NBS perfusion bioreactors where impellor-driven culture medium may not easily get into the inside portion of the paper carrier.
In some examples, a system controller 860 is configured to monitor and control the DO level, pH level, and temperature of the culture medium inside the reactor 822 and/or the perfusion column 842. The system controller 860 can also adjust the rotation of the rotor 828 and the speed of the pump 830 to achieve a desired medium condition and a desired flow rate for cell culture.
In some examples, the culture medium exiting the perfusion column 842 does not necessarily go into the harvest/waste collection 850. Instead, it can be re-circulated back into the medium reservoir 810 to be oxygenated again by the artificial lung 820 for reuse.
As shown in
2.3 System with a “Rotating Wheel”
The system 1400 includes a culture vessel 1410 at least partially filled with a gas (e.g., one or a combination of oxygen, carbon dioxide, nitrogen, and air). This culture vessel can be in cylindrical shape having two close ends 1412 or 1414, or configured with other types of geometry suitable for holding a cell culture medium. A rotatable shaft 1416 is positioned within the culture vessel 1410, for example, along a long axis defined by the two close ends of the culture vessel. A set of one or more disk members 1418 is concentrically mounted on the shaft 1416. The shaft 1416 can be driven by an actuator 1420 to rotate about its longitudinal axis, which in turn causes the disk members 1418 to rotate in the same manner. In this example, as the disk members 1418 are partially immersed in a culture medium, their rotation induces a relative movement of the culture medium with respect to an inner surface of the vessel 1410, which in turn accelerates the dissolution of oxygen molecules into the culture medium.
Cells can be grown in the oxygenated culture medium, for example, in suspension. The fluid conditions of the culture medium, for example, the temperature, DO level, and pH level, are monitored in real time using a set of sensors positioned inside the vessel 1410, for example, affixed to one end 1412. The measurements obtained by the sensors can be communicated, for example, in the form of electrical signals, to a control tower 1430. The control tower uses these measurement to determine the desired parameters of the system, for example, the rotational speed of the shaft 1416, the gaseous content inside the chamber, the rate of gas inflow (such as oxygen supply) if needed.
Further discussions about various embodiments of this rotating-wheel type of cell culture system are provided in U.S. Provisional Patent Application No. 61/168,740, titled “Bioreactors and Uses Thereof,” filed Apr. 13, 2009, the content of which is incorporated herein by reference.
In some examples, the wall of the culture vessel 1410 is configured to have microscopic surface features (e.g., similar to the surface features described with reference to the bioreactor 110 of
The following section describes various embodiments of a blood culture bioreactor for blood oxygenation as well as treatment of human diseases.
Shown in
Oxygenation of the blood takes place in the blood bioreactor/oxygenator of the blood oxygenation assembly 30. Various oxygenation methods can be used to introduce oxygen into the blood. A preferred oxygenation method is described in PCT/US06/37468 (WO2007/142664). The content of this application is incorporated herein by reference.
This method is neither sparging-based nor membrane-based conventional oxygen transfer method. It is based on dissolved oxygen (DO), namely generating microscopic bubbles in between water molecules. It takes advantage of the interaction between a material surface and a water current or other fluid (e.g., blood) current that generates dissolved oxygen or microscopic bubbles. The interaction breaks surface tension of the water or fluid current possibly at nanometer-scale level and generates microscopic air bubbles. Using this method, one can increase DO in the blood by repeatedly causing the blood to sweep or contact the air-exposed material surface with certain force.
The repeated sweeping can be generated in a housing, which defines a chamber having an inverted frusto-conical bottom or cone-shaped round bottom configured lower section as shown in
During the sweeping, oxygen diffuses and dissolves in the fluid phase (e.g., blood) and gases from the fluid (e.g., blood) such as carbon dioxide and nitrogen may diffuse into the gas phase. The gas stream exits the blood bioreactor/oxygenator via a vent or other fluid exit conduit. In one embodiment, the vent or other fluid exit conduit is closed so as to prevent the escape of bulk gas from the oxygenation assembly.
The assembly for supplying controlled flows or supplies of oxygen gas (e.g., gas supply assembly 40) includes a regulated source of oxygen gas, so that oxygen gas is delivered to the oxygenation assembly at a pressure greater than atmospheric pressure. Preferably, oxygen gas is supplied to the oxygenation assembly at a pressure greater than atmospheric pressure and less than about 50 p.s.i.a., the approximate maximum pressure that may be generated by commercially available blood pumps delivering blood. The assembly for supplying controlled flows or supplies of oxygen gas may be one of the many commercially available and clinically accepted oxygen delivery systems suitable for use with human patients (e.g., regulated bottled oxygen).
The assembly for supplying controlled flows or supplies of blood (e.g., blood supply assembly 10) includes a source of blood in combination with means for providing the blood to the oxygenation assembly. The blood to be oxygenated can be blood withdrawn from a patient, so that the blood supply assembly includes a blood inlet disposed along a portion of a catheter or other similar device at least partially removably insertable within the patient's body; a pump loop that in combination with the catheter or other device defines a continuous fluid pathway between the blood inlet and the oxygenation assembly; and a blood pump for controlling the flow of blood through the pump loop, i.e., the flow of blood provided to the oxygenation assembly. The blood pump may be one of the many commercially available and clinically accepted blood pumps suitable for use with human patients.
The flow characteristics of the oxygenated blood exiting the oxygenation assembly 30 will depend upon the circumstances surrounding the particular application involved. Typically, for example, the supply of oxygenated blood provided to a catheter for infusion to a patient's body will be a controlled flow defined by the flow parameters selected by the caregiver. In an application involving the sub-selective delivery of oxygenated blood for the treatment of ischemic tissues and/or the prevention of ischemia, flow rates of about 25-100 ml/min may be advantageous. Factors influencing the determination of blood flow characteristics may include one or more of the many clinical parameters or variables of the oxygenated blood to be supplied to the catheter or to be delivered to the patient, e.g., the size of the patient, the percentage of overall circulation to be provided, the size of the blood vessel to be accessed, hemolysis, hemodilution, pO2, pulsatility, mass flow rate, volume flow rate, temperature, hemoglobin concentration and pH.
The delivery assembly includes an elongated, generally tubular assembly including a central lumen and at least one end placeable within a patient body proximate a tissue site to be treated, the end including an outlet port for the oxygenated blood. The delivery assembly includes a catheter defining a fluid pathway, including a proximal portion adapted for coupling to the oxygenated blood supply assembly, and a distal portion defining a fluid pathway removably insertable within a patient's body, for infusing the oxygenated blood to predetermined sites. Alternatively, the delivery assembly may have an infusion guidewire, sheath, or other similar interventional device of the type used to deliver fluids to patients.
The system described above may include one or more gas bubble detectors, at least one of which is capable of detecting the presence of microbubbles, e.g., bubbles with diameters of about 100 μm to about 1000 μm. In addition, the system may include one or more macrobubble detectors to detect larger bubbles, such as bubbles with diameters of about 1000 μm or more. Such macrobubble detectors may include any suitable commercially available detector (e.g., those available from Transonic Inc. of New York), such as an outside, tube-mounted bubble detector including two transducers measuring attenuation of a sound pulse traveling from one side of the tube to the other. The microbubble and macrobubble detectors provide the physician or caregiver with a warning of potential clinically significant bubble generation. Such warnings also may be obtained through the use of transthoracic 2-D echo (e.g., to look for echo brightening of myocardial tissue) and the monitoring of other patient data.
The bubble detection system is able to discriminate between various size bubbles. Further, the bubble detection system operates continuously and is operatively coupled to the overall system so that an overall system shutdown occurs upon the sensing of a macrobubble. The system also may include various conventional items, such as sensors, flow meters (which also may serve a dual role as a macrobubble detector), or other clinical parameter monitoring devices; hydraulic components such as accumulators and valves for managing flow dynamics; access ports which permit withdrawal of fluids; filters or other safety devices to help ensure sterility; or other devices that generally may assist in controlling the flow of one or more of the fluids in the system. Any such devices are positioned within the system and used so as to avoid causing the formation of clinically significant bubbles within the fluid flow paths, and/or to prevent fluid flow disruptions, e.g., blockages of capillaries or other fluid pathways. Further, the system includes a biocompatible system acceptable for clinical use with human patients.
As mentioned above, oxygen is a crucial nutrient for animal cells and cell damage may result from oxygen deprivation for even brief periods of time, which may lead to organ dysfunction or failure.
For example, in patients suffering from acute myocardial infarction, if the myocardium is deprived of adequate levels of oxygenated blood for a prolonged period of time, irreversible damage to the heart can result. Where the infarction is manifested in a heart attack, the coronary arteries fail to provide adequate blood flow to the heart muscle. Angioplasty or stenting of occluded vessels are often used to treat to acute myocardial infarction or myocardial ischemia. However, the procedures may cause tissue injury and are not an attractive option for some patients. To reduce the risk of tissue injury typically associated with treatments of acute myocardial infarction and myocardial ischemia, it is desirable to deliver oxygenated blood or oxygen-enriched fluids to at-risk tissues. Tissue injury is minimized or prevented by the diffusion of the dissolved oxygen from the blood or fluids to the tissue and/or blood perfusion that removes metabolites and that provides other chemical nutrients. In some cases, the treatment of acute myocardial infarction and myocardial ischemia includes perfusion of oxygenated blood or oxygen-enriched fluids.
The system described above can be used for preparation and delivery of oxygenated blood, e.g., hyperoxemic or hyperbaric blood, to a specific location within a patient's body. The system may include an extracorporeal circuit for oxygenating blood, e.g., increasing the level of oxygen in the blood, in which the blood to be oxygenated is blood withdrawn from the patient. The system also may be used for regional or localized delivery of oxygenated blood. For example, one can withdraw blood from a patient, circulate it through the above-described system to increase blood oxygen concentration, and then deliver the blood back to the patient.
The system and method describe above can be use to treat or prevent ischemia. Factors influencing the determination of blood flow characteristics for the extracorporeal circuit may include one or more of the many clinical parameters or variables of the oxygenated blood to be supplied to the patient, e.g., the size of the patient, the percentage of overall circulation to be provided, the size of the target to be accessed, hemolysis, hemodilution, pO2, pulsatility, mass flow rate, volume flow rate, temperature, hemoglobin concentration and pH.
The system and method describe above can also be used to treat a patient having a lung failure or other respiratory disorders such as acute respiratory distress syndrome (ARDS), which interfere with oxygenation of blood. For that purpose, one can identify a subject (a human or non-human animal) having the condition and apply the procedure described herein.
The system may be used in conjunction with angiographic or guiding catheters, arterial sheaths, and/or other devices used in angioplasty and in other interventional cardiovascular procedures. The system may be used in applications involving one or more vascular openings, i.e., in either contralateral or ipsilateral procedures.
In contralateral procedures blood is withdrawn from the patient at a first location, e.g., the left femoral artery. The oxygenated blood is returned to the patient at a second location proximate the tissue to be treated. Blood oxygenation occurs as the blood pumped through the extracorporeal circuit or loop passes through an oxygenation assembly and forms the oxygenated blood to be delivered. In applications where the system includes a catheter, the catheter may include a distal end removably insertable within a patient's body through a second location, such as the patient's right femoral artery. The distal end includes at least one port in fluid communication with the central lumen and through which the oxygenated blood may exit. Further, the distal portion of the catheter may be adapted with a tip portion shaped so as to promote insertion of the device, such as through the same sheath used for interventional procedures like angioplasty, to specific predetermined locations within a patient's body. Examples of tip portion shapes which may be used include any of the standard clinically accepted tip configurations used with devices like guide catheters for providing access to and for holding in locations like the coronary ostium. Accordingly, the method may further include the step of positioning the portion of the distal end of the catheter including the fluid exit port at a predetermined location within a patient body proximate to the tissue to be treated.
In ipsilateral procedures, the system may be used along with one or more of any of a number of suitable, standard-size, clinically accepted guide catheters and/or introducer sheaths. The system, for example, may comprise a catheter, a catheter and guide catheter, or a catheter and sheath, for use within a guide catheter or introducer sheath used for the primary interventional procedure.
The present invention may also be useful in other medical applications, such as cancer therapy (e.g., the delivery of oxygen-enriched fluids directly into poorly vascularized tumors during radiation or chemotherapy treatments), neurovascular applications (e.g., the treatment of stroke and cerebral trauma patients), lung support in trauma and lung disease patients, and wound care management. Also, although the present invention may be used to raise oxygen levels, for example, in venous and arterial blood, in blood substitutes, e.g., perfluorocarbons, and in combinations thereof, for the sake of clarity and convenience reference is made herein only to arterial blood.
Further, the present invention also may be used in connection with drug fluid infusion therapies to prevent ischemia and/or to otherwise enhance the effectiveness of the therapies. Examples of drug fluids used in cardiovascular and neurological procedures which may be infused (either before, after or along with the oxygenated blood) in accordance with the present invention include, without limitation, vasodilators (e.g., nitroglycerin and nitroprusside), platelet-actives (e.g., ReoPro and Orbofiban), thrombolytics (e.g., t-PA, streptokinase, and urokinase), antiarrhythmics (e.g., lidocaine, procainamide), beta blockers (e.g., esmolol, inderal), calcium channel blockers (e.g., diltiazem, verapamil), magnesium, inotropic agents (e.g., epinephrine, dopamine), perofluorocarbons (e.g., fluosol), crystalloids (e.g., normal saline, lactated ringers), colloids (albumin, hespan), blood products (packed red blood cells, platelets, whole blood), Na+/H+ exchange inhibitors, free radical scavengers, diuretics (e.g., mannitol), antiseizure drugs (e.g., phenobarbital, valium), and neuroprotectants (e.g., lubeluzole). The drug fluids may be infused either alone or in combination depending upon the circumstances involved in a particular application, and further may be infused with agents other than those specifically listed, such as with adenosine (Adenocard, Adenoscan, Fujisawa), to reduce infarct size or to effect a desired physiologic response.
The pump assembly 20 provides the blood to a blood oxygenation assembly 30. The oxygenation assembly 30 has an apparatus for raising the pO2 of the blood, advantageously to hyperoxemic or hyperbaric levels. The oxygenation assembly 30 oxygenates blood received from the pump assembly 20. The oxygenated blood is then provided to a delivery assembly 70 for delivery to a desired location. Blood oxygenation occurs at least in part at a pressure greater than atmospheric pressure, and the oxygenated blood is delivered with a concomitant pressure drop, so that the formation of clinically significant bubbles is avoided, i.e., blood oxygenation and delivery occurs bubble-free.
What constitutes bubble-free delivery will vary depending upon the circumstances involved in a particular application. Advantageously, bubble-free delivery will occur with a complete absence of bubbles. However, in some cases of “bubble-free” delivery, one or more (perhaps maybe even thousands of) non-clinically-significant bubbles may be delivered, particularly where the gas bubbles comprise oxygen gas bubbles, which are thought to be more readily accepted by the body than bubbles of other gases. Moreover, a clinically acceptable level of bubbles in one application (e.g., a coronary procedure) might not prove to be clinically acceptable in another application (e.g., a neurological procedure).
The system shown in
The system shown in
The oxygenated blood preferably is provided to a patient at about 37° C. In some instances, cooling of the oxygenated blood may be desired, e.g., to induce local or regional hypothermia (e.g., temperatures below about 35° C.). For example, in neurological applications such cooling may be desired to achieve a neuroprotective effect. Hypothermia also may be regarded as an advantageous treatment or preservation technique for ischemic organs, organ donations, or reducing metabolic demand during periods of reduced perfusion.
The system described herein may include a heat exchanger assembly operable to maintain, to increase, or to decrease the temperature of the oxygenated blood as desired in view of the circumstances involved in a particular application. The temperatures for the oxygenated blood in the range of about 35° C. to about 37° C. generally will be desired, although blood temperatures outside that range (e.g., 29° C.) may be more advantageous provided that patient core temperature remains at safe levels in view of the circumstances involved in the particular application. Temperature monitoring may occur, e.g., with one or more thermocouples, thermistors or temperature sensors integrated into the electronic circuitry of a feedback controlled system, so that an operator may input a desired perfusate temperature with an expected system response time of seconds or minutes depending upon infusion flow rates and other parameters associated with the active infusion of cooled oxygenated blood. Examples of heat exchange assemblies suitable for use with the present system, either alone or integrated with a system component, include any of the numerous commercially available and clinically accepted heat exchanger systems used in blood delivery systems today, e.g., heat exchangers, heat radiating devices, convective cooling devices and closed refrigerant devices. Such devices may include, e.g., conductive/convective heat exchange tubes, made typically of stainless steel or high strength polymers, in contact with blood on one side and with a coolant on the other side.
The following specific examples are to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever. Without further elaboration, it is believed that one skilled in the art can, based on the description herein, utilize the present invention to its fullest extent. All publications cited herein are hereby incorporated by reference in their entirety.
A fed-batch-culture process of CHO cells was examined using the cell culture system of
Using the same cell culture system, a fed-batch-culture process of VERO cells was examined. The cells were cultured with microcarriers in a serum-free suspension culture medium for assumed virus production phase.
Outside-body blood oxygen transfer and safe culture are important for life-saving medical devices. In this example, a 5-liter current suspension bioreactor was used to oxygenate goat whole blood. The current suspension bioreactor was similar to that shown in
Similar experiments were performed in a rabbit by using the bioreactors shown in
Taken together, the results indicate that the above-described current suspension bioreactors can be used as artificial lungs for oxygenating whole blood culture in vitro and returning oxygenated blood to animals.
Perfusion bioreactors (
As shown in Table 2, the cells were cultured at very high densities and the total cell yields were also high. For example, the results indicate that the yield or productivity of a 150 L paper-carrier perfusion bioreactor equaled to that of a 1500 liter fed-batch deep tank bioreactor. The results demonstrate that the bioreactor provides a simple single-use system with stable production process.
The above-described perfusion bioreactors (5 liter) were used to culture Vero, MDCK, BHK-21, Marc 145, and other cells in DMEM/F12 medium in the presence of 10% FBS in the same manner described above. As shown in
A similar experiment was performed using a 50-Liter perfusion bioreactor in which VERO cells were grown to a density of 6.5×108 cells/g in a total of 1200 g of paper carrier. The results indicate that the productivity of a 50 L paper carrier perfusion bioreactor was about 1200 times that of a 20-liter conventional roller bottle used for industrial vaccine production. One advantage of such a bioreactor is the super-growth strength due to high density cell culture and inter-cell secreting growth factor support.
Experiments were conducted to test the effectiveness of the above-described cell culture systems for recombinant protein production.
It was found that, for protein production, the perfusion bioreactor system worked well for high density perfusion cell culture and this system was able to culture high titer cell lines without much cell line development and process development. It was also found that, in the systems, the cells were faster to reach the production stage than conventional suspension-adapted cells.
In some experiments, a fed-perfusion culture process was examined by using a CHOK1-adapted suspension cell line expressing EPO analogue (EPO-hyperG) in a serum-free suspension culture medium for production phase. It was clearly shown that CHOK1 cells in the cell column have optimal DO level, cell density, and yield of the product (Table 4).
In addition, experiments were conducted to test the culture system with the rotating bioreactor of
A similar experiment was conducted using a 5-liter work volume suspension culture bioreactor (
The blood oxygenation system shown in
An experiment similar to that in example 6 was conducted to study if the above-described blood oxygenation system could be used as an artificial lung to treat partial lung functional failure.
In brief, the blood oxygenation system (
Goat blood culture was inoculated with E. coli and cultured in the blood oxygenation system described above. Meanwhile, the inoculated culture was subject to low-dose r-irradiation treatment to remove the E. coli cells. It was found, that after the r-irradiation treatment and continuing culture, no significant E. coli proliferation was observed in the cultured blood. The while red blood cells and platelet were morphologically normal under microscope. The results suggest that the blood culture bioreactor, when combined with low-dose r-irradiation treatment, can be used to treat bacteria or virus infection in humans or non-human animals.
An experiment similar to that in example 8 was also conducted. In brief, E. coli was inoculated to a goat through vein injection. After re-circulating goat blood for 9 liters (about 3× total goat blood volume) per day for 3 days together with a low-dose r-irradiation treatment, no significant E. coli proliferation in the blood culture was observed. In contrast, a control goad was inoculated with E. coli. Its blood was subject to the same procedure except the low-dose r-irradiation treatment. It was found that the control goat died at day 2. These results demonstrate the blood culture bioreactor, when combined with low-dose r-irradiation treatment, can be used to treat bacteria or virus infection in humans or non-human animals.
The above-described blood re-circulating and the low-dose r-irradiation treatment (
Experiments were conducted to remove white blood cells from the re-circulating blood of a goat.
Briefly, goat blood was obtained and cultured in the same manner described above. The goat blood within the bioreactor of the blood oxygenation system (
The blood oxygenation system shown
Briefly, a goat was subject to an in vitro blood oxygenation-re-circulation procedure using the blood oxygenation system in the same manner described above. The blood from the goat was inoculated with CHO cells within the culture vessel and then exposed to low-dosage γ-irradiation so as to remove the CHO cells. After re-circulating the goat blood for 9 liters (about 3× of the total goat blood volume), no significant CHO proliferation in the blood culture was observed while non-CHO cell proliferation was observed in non-treated CHO-seeded blood culture.
The results suggest that the procedure can be used to remove nucleated cells (such as leukemia cells) from blood and therefore can be used to treat human cancer and tumor metastasis such as leukaemia, lymphoma, and sarcoma. It should be noted that this low-dosage r-irradiation does not hurt read blood cells and platelet since they do not have nuclear DNA.
A rotating wheel bioreactor (
The rotating wheel bioreactor was used to culture suspension cells. Specifically, a 150-liter work volume rotating wheel bioreactor (
The rotating wheel bioreactor (
Many of the features disclosed in this specification may be combined in various combinations. Each feature disclosed in this specification may be replaced by an alternative feature serving the same, equivalent, or similar purpose.
From the above description, one skilled in the art can easily ascertain the essential characteristics of the present invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions. Thus, other embodiments are within the scope of the following claims.
This application claims the benefit of U.S. Provisional Application No. 61/183,387, titled “Novel Bioreactors,” filed Jun. 2, 2009, U.S. Provisional Application No. 61/216,193, titled “Blood Culture Bioreactor,” filed May 14, 2009, U.S. Provisional Application No. 61/192,515, titled “Novel Bioreactors,” filed Sep. 19, 2008, and U.S. Provisional Application No. 61/132,190, titled “Novel Bioreactors,” filed Jun. 16, 2008. The content of each of the above four applications is incorporated herein by reference in its entirety.
Number | Date | Country | |
---|---|---|---|
61132190 | Jun 2008 | US | |
61192515 | Sep 2008 | US | |
61216193 | May 2009 | US | |
61183387 | Jun 2009 | US |